<DOC>
	<DOCNO>NCT00300950</DOCNO>
	<brief_summary>The GI-4000 therapeutic vaccine placebo inject skin post-resection , non-metastatic pancreas cancer patient . Patients monitor recurrence well safety , immune response related injection .</brief_summary>
	<brief_title>Safety Efficacy Therapeutic Vaccine GI-4000 Combination With Gemcitabine Versus Placebo Treatment Non-metastatic , Post-resection Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>( A general item require ) Patients nonmetastatic pancreas cancer postresection productrelated ras mutation &gt; 18 year age Negative skin test hypersensitivity Saccharomyces cerevisiae Metastatic pancreas cancer patient postresection Patients productrelated ras mutation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pancreas Cancer</keyword>
	<keyword>resect pancreas cancer</keyword>
	<keyword>non-metastatic pancreas cancer</keyword>
</DOC>